The results of recent studies, presented at the recent meeting of the American Headache Society, concerning the new drugs that could prevent migraines, are definitely good news for the 30 million American people who are currently affected by this problem.
The above mentioned meeting, that took place in Washington, D.C., between the 18th and 21rst of June, presented a new class of drugs that shows optimistic premises towards not only the curing of migraines but, in fact, on their prevention.
Be it only light, brief headaches or truly intense and severe migraines, these seriously affect individuals’ levels of being and functioning properly. They represent a real source of distress for a large number of persons throughout the whole country.
The new type of medication that promises results in combating but also preventing migraines is characterized by the fact that it targets a biochemical named calcitonin gene-related peptide (CGRP). CGRP is considered the main cause of migraines.
There are four manufacturers of drugs who reported that they are conducting experimental trials on their variants of CGRP monoclonal antibodies. These manufacturers are : Teva Pharmaceuticals, Eli Lilly and Company, Amgen, Alder Pharmaceuticals.
Incipient tests proved efficiency of the CGRP monoclonal antibodies in preventing migraines, for about 50 percent of patients who tried the treatment. So far, there haven’t been recorded serious or various adverse effects of the drugs in question.
In fact, results of clinical trials, phase II conclude that half of patients declared they actually experienced a reduction of about 50 percent in their migraines.
One less positive side of this new type of drugs may be represented by the fact that it needs to be administered by means of an injection. However, this procedure should take place only once a month.
It may take more time before the drugs will actually be available on the market, for migraines sufferers, due to the fact that it is still in experimental stage. However, it is expected to become a genuine source of relief, especially due to its promise of preventing migraines.
This is actually one thing that should differentiate this new type of anti-migraine medication from the already numerous products that already exist on the market today: the fact that it aims to prevent rather than cure the sufferance.